FN1 and type 2 diabetes mellitus: To our knowledge, this study is the first to report increased levels of ECM-related markers, specifically the most abundant non-collagenous glycoproteins of GBM—fibronectin and laminin—in the urine of obese, newly diagnosed patients with T2DM during anti-diabetic therapy with metformin.